Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by M101on Aug 09, 2021 12:58pm
88 Views
Post# 33672403

RE:RE:RE:RE:New Corporate Update

RE:RE:RE:RE:New Corporate UpdateI've never put any value on the covid stuff, it's not a major expense compared to exec compensation so anything it might produce beyond PR is a bonus. 

As for the phase 1 financing wait, well that's the only thing holding the stock back isn't it? If you want to invest after that's been settled then less risk implies less reward.  

I continue to believe there is no news until after labour day but we'll see the trading pattern start to diverge by the end of the month, if it hasn't already.  We just saw pp sellers rush into this mini rally today but they've always backed off when the peak turns into a dip, except in the fall when the next financing usually becomes inevitable. This fall it will not be inevitable and Goldstein is not out there making weasly deals to maintain his control at our expense. 




 
<< Previous
Bullboard Posts
Next >>